Skip to content
10-Q

Quarterly Report

TONIX PHARMACEUTICALS HOLDING CORP. TNXP

0001999371-26-010486

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 15.94M sh
Shares Diluted Q1 2026 · Mar 31, 2026 13.71M sh
Shares Diluted Q1 2026 · Mar 31, 2025 5.93M sh
Capex Q1 2026 · Mar 31, 2026 $1.69M
Capex Q1 2026 · Mar 31, 2025 $6K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$42.32M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$16.58M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $185.47M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $207.64M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $131.72M
Stockholders Equity Q1 2026 · Mar 31, 2026 $227.14M
Stockholders Equity Q1 2026 · Dec 31, 2025 $245.15M
Stockholders Equity Q1 2026 · Mar 31, 2025 $180.4M
Stockholders Equity Q1 2026 · Dec 31, 2024 $139.56M
Current Liabilities Q1 2026 · Mar 31, 2026 $29.65M
Current Liabilities Q1 2026 · Dec 31, 2025 $30.84M
Total Liabilities Q1 2026 · Mar 31, 2026 $30.78M
Total Liabilities Q1 2026 · Dec 31, 2025 $32.02M
Current Assets Q1 2026 · Mar 31, 2026 $207.17M
Current Assets Q1 2026 · Dec 31, 2025 $228.88M
Total Assets Q1 2026 · Mar 31, 2026 $257.91M
Total Assets Q1 2026 · Dec 31, 2025 $277.17M
Eps Diluted Q1 2026 · Mar 31, 2026 −$2.93
Eps Diluted Q1 2026 · Mar 31, 2025 −$2.84
Eps Basic Q1 2026 · Mar 31, 2026 −$2.93
Eps Basic Q1 2026 · Mar 31, 2025 −$2.84
Sga Expense Q1 2026 · Mar 31, 2026 $28.62M
Sga Expense Q1 2026 · Mar 31, 2025 $10.1M
Rd Expense Q1 2026 · Mar 31, 2026 $18.21M
Rd Expense Q1 2026 · Mar 31, 2025 $7.44M
Net Income Q1 2026 · Mar 31, 2026 −$40.19M
Net Income Q1 2026 · Mar 31, 2025 −$16.83M
Operating Income Q1 2026 · Mar 31, 2026 −$41.54M
Operating Income Q1 2026 · Mar 31, 2025 −$16.05M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $1.58M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $943K
Revenue Q1 2026 · Mar 31, 2026 $6.88M
Revenue Q1 2026 · Mar 31, 2025 $2.43M
Stock Repurchased Q1 2026 · Mar 31, 2025 $3.05M